Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation

Experimental Hematology

Volumn 41, Issue 5, 2013, Pages 444-461.e4

  Ortlepp, Claudia ^a   Steudel, Christine ^a   Heiderich, Caroline ^a   Koch, Sina ^a   Jacobi, Angela ^a   Ryser, Martin ^a   Brenner, Sebastian ^a   Bornhäuser, Martin ^a   Brors, Benedikt ^b   Hofmann, Wolf Karsten ^c   Ehninger, Gerhard ^a   Thiede, Christian ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOTAXIN; CD135 ANTIGEN; CD34 ANTIGEN; MESSENGER RNA; RETROVIRUS VECTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOCRINE EFFECT; BONE MARROW CELL; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; FLT3 RECEPTOR GENE; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INTERNAL TANDEM DUPLICATION MUTATION; LEUKEMIA CELL; LYMPHOID CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

EID: 84876836615     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.01.007     Document Type: Article

References (56)

1. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
2. Nakao M., Yokota S., Iwai T., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
3. Yamamoto Y., Kiyoi H., Nakano Y., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97:2434-2439.
4. Small D. FLT3 mutations: biology and treatment. American Society of Hematology 2006, 1:178-184.
5. Choudhary C., Schwable J., Brandts C., et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 2005, 106:265-273.
6. Grundler R., Miething C., Thiede C., Peschel C., Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005, 105:4792-4799.
7. Small D. Targeting FLT3 for the treatment of leukemia. Sem Hematol 2008, 45:S17-S21.
8. Bacher U., Haferlach C., Kern W., Haferlach T., Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters - an analysis of 3082 patients. Blood 2008, 111:2527-2537.
9. Mead A.J., Linch D.C., Hills R.K., et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007, 110:1262-1270.
10. Stracke M.L., Krutzsch H.C., Unsworth E.J., et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992, 267:2524-2529.
11. Tokumura A., Majima E., Kariya Y., et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002, 277:39436-39442.
12. Umezu-Goto M., Kishi Y., Taira A., et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002, 158:227-233.
13. Choi J.W., Lee C.W., Chun J. Biological roles of lysophospholipid receptors revealed by genetic null mice: An update. Biochim Biophys Acta 2008, 1781:531-539.
14. Pasternack S.M., von Kugelgen I., Al Aboud K., et al. G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet 2008, 40:329-334.
15. Anliker B., Chun J. Cell surface receptors in lysophospholipid signaling. Semin Cell Dev Biol 2004, 15:457-465.
16. van Meeteren L.A., Moolenaar W.H. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 2007, 46:145-160.
17. Chen M., O'Connor K.L. Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 2005, 24:5125-5130.
18. Lee H.Y., Bae G.U., Jung I.D., et al. Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells. FEBS Lett 2002, 515:137-140.
19. Tokumura A., Kume T., Fukuzawa K., et al. Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity. Life Sci 2007, 80:1641-1649.
20. Yang Y., Mou L., Liu N., Tsao M.S. Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 1999, 21:216-222.
21. Jing D.H., Fonseca A.V., Alakel N., et al. Hematopoietic stem cells in co-culture with mesenchymal stromal cells-modeling the niche compartments in vitro. Haematologica 2010, 95:542-550.
22. Oswald J., Steudel C., Salchert K., et al. Gene-expression profiling of CD34(+) hematopoietic cells expanded in a collagen I matrix. Stem Cells 2006, 24:494-500.
23. Bolstad B.M., Irizarry R.A., Astrand M., Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.
24. Irizarry R.A., Hobbs B., Collin F., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
25. Irizarry R.A., Bolstad B.M., Collin F., et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31:e15.
26. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Nat Acad Sci USA 2001, 98:10515.
27. Camon E., Magrane M., Barrell D., et al. The Gene Ontology Annotation (GOA) Database: sharing knowledge in Uniprot with Gene Ontology. Nucleic Acids Res 2004, 32:D262-D266.
28. R Foundation for Statistical Computing. R: a language and environment for statistical computing. Vienna, Austria: 2003.
29. Duong C.Q., Bared S.M., Abu-Khader A., et al. Expression of the lysophospholipid receptor family and investigation of lysophospholipid-mediated responses in human macrophages. Biochim Biophys Acta 2004, 1682:112-119.
30. Koch S., Jacobi A., Ryser M., Ehninger G., Thiede C. Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis. Cells Tissues Organs 2008, 188:225-235.
31. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995, 57:289-300.
32. Samadi N., Gaetano C., Goping I.S., Brindley D.N. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 2009, 28:1028-1039.
33. Koike S., Keino-Masu K., Ohto T., Masu M. The N-terminal hydrophobic sequence of autotaxin (ENPP2) functions as a signal peptide. Genes Cells 2006, 11:133-142.
34. Jansen S., Stefan C., Creemers J.W., et al. Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase. D J Cell Sci 2005, 118:3081-3089.
35. Ferguson C.G., Bigman C.S., Richardson R.D., et al. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org Lett 2006, 8:2023-2026.
36. Weisberg E., Boulton C., Kelly L.M., et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002, 1:433-443.
37. Spiekermann K., Dirschinger R.J., Schwab R., et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 2003, 101:1494-1504.
38. + hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998, 91:4523-4530.
39. Kranenburg O., Moolenaar W.H. Res-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene 2001, 20:1540-1546.
40. Koh E., Clair T., Woodhouse E.C., et al. Site-directed mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities. Cancer Res 2003, 63:2042-2045.
41. Kishi Y., Okudaira S., Tanaka M., et al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 2006, 281:17492-17500.
42. Ohta H., Sato K., Murata N., et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 2003, 64:994-1005.
43. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000, 111:190-195.
44. Kiyoi H., Naoe T., Nakano Y., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93:3074-3080.
45. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
46. Chiang C.L., Chen S.S.A., Lee S.J., et al. Lysophosphatidic acid induces erythropoiesis through activating lysophosphatidic acid receptor 3. Stem Cells 2011, 29:1763-1773.
47. Pebay A., Bonder C.S., Pitson S.M. Stem cell regulation by lysophospholipids. Prostaglandins Other Lipid Mediat 2007, 84:83-97.
48. Ryser M.F., Ugarte F., Lehmann R., Bornhauser M., Brenner S. S1P(1) overexpression stimulates S1P-dependent chemotaxis of human CD34+hematopoietic progenitor cells but strongly inhibits SDF-1/CXCR4-dependent migration and in vivo homing. Mol Immunol 2008, 46:166-171.
49. + cell lines expressing the S1P1 receptor: Possible contribution to progenitor cell trafficking. Blood 2004, 104:732A.
50. Yanai N., Matsui N., Furusawa T., Okubo T., Obinata M. Sphingosine-1-phosphate and lysophosphatidic acid trigger invasion of primitive hematopoietic cells into stromal cell layers. Blood 2000, 96:139-144.
51. Cools J., Quentmeier H., Huntly B.J., et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2004, 103:2802-2805.
52. Buitenhuis M., Verhagen L.P., Cools J., Coffer P.J. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 2007, 67:3759-3766.
53. Mizuki M., Fenski R., Halfter H., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000, 96:3907-3914.
54. Hamaguchi H., Nagata K., Yamamoto K., et al. Establishment of a novel human myeloid leukaemia cell line (FKH-1) with t(6;9)(p23;q34) and the expression of dek-can chimaeric transcript. Br J Haematol 1998, 102:1249-1256.
55. Nishimasu H., Okudaira S., Hama K., et al. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol 2011, 18:205-212.
56. Kishimoto T., Soda Y., Matsuyama Y., Mizuno K. An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. Clin Biochem 2002, 35:411-416.